Monte Rosa Therapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Operating Expenses Growth & History (GLUE)
Monte Rosa Therapeutics's operating expenses was $177.9M for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $177.9M | $21.1M | +13.49% |
| 2024 | 2024-12-31 | $156.7M | $13.4M | +9.37% |
| 2023 | 2023-12-31 | $143.3M | $30.9M | +27.52% |
| 2022 | 2022-12-31 | $112.4M | $39.5M | +54.20% |
| 2021 | 2021-12-31 | $72.9M | $44.9M | +160.20% |
| 2020 | 2020-12-31 | $28.0M | — | — |
Monte Rosa Therapeutics quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $58.1M | $19.4M | +49.94% |
| Q1 2026 | 2026-03-31 | $54.2M | $13.4M | +32.65% |
| Q4 2025 | 2025-12-31 | $52.5M | $4.9M | +10.19% |
| Q3 2025 | 2025-09-30 | $45.7M | $10.0M | +27.98% |
| Q2 2025 | 2025-06-30 | $38.7M | $1.4M | +3.78% |
| Q1 2025 | 2025-03-31 | $40.9M | $4.9M | +13.56% |
| Q4 2024 | 2024-12-31 | $47.6M | $12.8M | +36.66% |
| Q3 2024 | 2024-09-30 | $35.7M | −$1.2M | −3.31% |
| Q2 2024 | 2024-06-30 | $37.3M | $116,000 | +0.31% |
| Q1 2024 | 2024-03-31 | $36.0M | $1.8M | +5.11% |
| Q4 2023 | 2023-12-31 | $34.9M | $2.4M | +7.31% |
| Q3 2023 | 2023-09-30 | $37.0M | $8.6M | +30.34% |
| Q2 2023 | 2023-06-30 | $37.2M | $10.0M | +36.69% |
| Q1 2023 | 2023-03-31 | $34.3M | $10.0M | +40.97% |
| Q4 2022 | 2022-12-31 | $32.5M | $9.1M | +38.92% |
| Q3 2022 | 2022-09-30 | $28.4M | $8.5M | +42.75% |
| Q2 2022 | 2022-06-30 | $27.2M | $9.1M | +50.26% |
| Q1 2022 | 2022-03-31 | $24.3M | $12.8M | +111.25% |
| Q4 2021 | 2021-12-31 | $23.4M | — | — |
| Q3 2021 | 2021-09-30 | $19.9M | $13.5M | +211.12% |
| Q2 2021 | 2021-06-30 | $18.1M | $12.7M | +235.86% |
| Q1 2021 | 2021-03-31 | $11.5M | — | — |
| Q3 2020 | 2020-09-30 | $6.4M | — | — |
| Q2 2020 | 2020-06-30 | $5.4M | — | — |
Monte Rosa Therapeutics operating expenses trends
Over the last five fiscal years, Monte Rosa Therapeutics's operating expenses increased from $28.0M to $177.9M, a change of $149.9M. The latest reported quarter, Q2 2026, shows $58.1M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗